| 貨號 | 規(guī)格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數(shù)量 |
|---|---|---|---|---|---|---|---|
S83993-2mg |
99.3% | ￥260.00 | 3 | - | - | - |
|
S83993-5mg |
99.3% | ￥400.00 | 6 | - | - | - |
|
S83993-10mg |
99.3% | ￥550.00 | 6 | - | - | - |
|
S83993-25mg |
99.3% | ￥1100.00 | 5 | - | - | - |
|
S83993-50mg |
≥99% | ￥2000.00 | 貨期：2-3天 | - | - | - |
|
S83993-100mg |
≥99% | ￥3800.00 | 貨期：2-3天 | - | - | - |
|
PHCCC is a Group I mGluR antagonist with an IC50 of 3 μM. PHCCC is a selective positive modulator of mGlu4 receptor. Antiparkinsonian effect
| 產(chǎn)品描述： | PHCCC is a Group I mGluR antagonist with an IC50 of 3 μM. PHCCC is a selective positive modulator of mGlu4 receptor. Antiparkinsonian effect | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | Group I mGluR receptors:3 μM (IC50);GluR | ||||||||||||||||||||
| 體外研究： | PHCCC potentiated the effect of L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) in inhibiting transmission at the striatopallidal synapse | ||||||||||||||||||||
| 體內研究： | PHCCC (75 nmol/2.5 μl; intracerebroventricular) produces an antiparkinsonian effect in a dopamine depletion akinesia model | ||||||||||||||||||||
| 參考文獻： | 1. Récasens M, et al. Metabotropic glutamate receptors as drug targets. Curr Drug Targets. 2007;8(5):651-681. 2. Marino MJ et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13668-73. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號
危險品化學品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京